Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma

• DOI: 10.18632/aging.202380
• Publication Date: 2021-01-22T15:24:48Z
• Authors: Pengfei Zhu; Ruo Feng; Xu Lu; Yuan Liao; Zhicheng Du; Wenlong Zhai; Kunlun Chen
• Keywords: Male; 0301 basic medicine; 0303 health sciences; Carcinoma, Hepatocellular; Liver Neoplasms; Aldo-Keto Reductase Family 1 Member C3; Down-Regulation; Hep G2 Cells; Middle Aged; Prognosis; 3. Good health; 03 medical and health sciences; Gene Ontology; Area Under Curve; Case-Control Studies; Cell Line, Tumor; Gene Knockdown Techniques; Humans; Female; Protein Interaction Maps; RNA, Messenger; Oxidoreductases; Research Paper; Cell Proliferation; Proportional Hazards Models

Hepatocellular carcinoma (HCC) is the most common histological type of primary liver cancer and the majority of patients are diagnosed at an advanced stage and have a poor prognosis. AKR1C3 (Aldo-keto reductase family 1 member C3) and AKR1D1 (Aldo-keto reductase family 1 member D1) catalyze the conversion of aldehydes and ketones to alcohols and play crucial roles in multiple cancers. However, the functions of AKR1C3 and AKR1D1 in HCC remain unclear. In our study, data from the public databases were selected as training and validation sets, then 76 HCC patients in our center were chosen as a test set. Bioinformatics methods suggested AKR1C3 was overexpressed in HCC and AKR1D1 was down-regulated. The receiver operating characteristic curve (ROC) analysis was performed and the area under curve (AUC) values of AKR1C3 and AKR1D1 were above 0.7 (0.948, 0.836, respectively). Also, the high expression of AKR1C3 and low expression of AKR1D1 predicted poor prognosis and short median survival time. Then, the knockdown of AKR1C3 and overexpression of AKR1D1 in HCC cells were achieved with lentivirus. And both decreased cell proliferation, restrained cell viability, and inhibited tumorigenesis. Moreover, the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted and the results showed that AKR1C3 and AKR1D1 might participate in the MAPK/ERK and androgen receptor (AR) signaling pathway. Furthermore, the AR and phosphorylated ERK1/2 were significantly reduced after the suppression of AKR1C3 or overexpression of AKR1D1. Collectively, AKR1C3 and AKR1D1 might serve as candidate diagnostic and prognostic biomarkers for HCC and provide potential targets for HCC treatment.